Abstract
The mechanisms underlying cellular drug resistance have been extensively studied, but little is known about its regulation. We have previously reported that activating transcription factor 4 (ATF4) is upregulated in cisplatin-resistant cells and plays a role in cisplatin resistance. Here, we find out a novel relationship between the circadian transcription factor Clock and drug resistance. Clock drives the periodical expression of many genes that regulate hormone release, cell division, sleep-awake cycle and tumor growth. We demonstrate that ATF4 is a direct target of Clock, and that Clock is overexpressed in cisplatin-resistant cells. Furthermore, Clock expression significantly correlates with cisplatin sensitivity, and that the downregulation of either Clock or ATF4 confers sensitivity of A549 cells to cisplatin and etoposide. Notably, ATF4-overexpressing cells show multidrug resistance and marked elevation of intracellular glutathione. The microarray study reveals that genes for glutathione metabolism are generally downregulated by the knockdown of ATF4 expression. These results suggest that the Clock and ATF4 transcription system might play an important role in multidrug resistance through glutathione-dependent redox system, and also indicate that physiological potentials of Clock-controlled redox system might be important to better understand the oxidative stress-associated disorders including cancer and systemic chronotherapy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Annereau JP, Szakacs G, Tucker CJ, Arciello A, Cardarelli C, Collins J et al. (2004). Analysis of ATP-binding cassette transporter expression in drug-selected cell lines by a microarray dedicated to multidrug resistance. Mol Pharmacol 66: 1397–1405.
Arao T, Yanagihara K, Takigahira M, Takeda M, Koizumi F, Shiratori Y et al. (2006). ZD6474 inhibits tumor growth and intraperitoneal dissemination in a highly metastatic orthotopic gastric cancer model. Int J Cancer 118: 483–489.
Blais JD, Filipenko V, Bi M, Harding HP, Ron D, Koumenis C et al. (2004). Activating transcription factor 4 is translationally regulated by hypoxic stress. Mol Cell Biol 24: 7469–7482.
Canaple L, Kakizawa T, Laudet V . (2003). The days and nights of cancer cells. Cancer Res 63: 7545–7552.
Chaney SG, Sancar A . (1996). DNA repair: enzymatic mechanisms and relevance to drug response. J Natl Cancer Inst 88: 1346–1360.
Cui Y, Konig J, Buchholz JK, Spring H, Leier I, Keppler D . (1999). Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. Mol Pharmacol 55: 929–937.
Deeley RG, Westlake C, Cole SP . (2006). Transmembrane transport of endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins. Physiol Rev 86: 849–899.
Dickinson DA, Forman HJ . (2002). Cellular glutathione and thiols metabolism. Biochem Pharmacol 64: 1019–1026.
Fawcett TW, Martindale JL, Guyton KZ, Hai T, Holbrook NJ . (1999). Complexes containing activating transcription factor (ATF)/cAMP-responsive-element-binding protein (CREB) interact with the CCAAT/enhancer-binding protein (C/EBP)-ATF composite site to regulate Gadd153 expression during the stress response. Biochem J 339: 135–141.
Fojo T, Bates S . (2003). Strategies for reversing drug resistance. Oncogene 22: 7512–7523.
Fu L, Pelicano H, Liu J, Huang P, Lee C . (2002). The circadian gene Period2 plays an important role in tumor suppression and DNA damage response in vivo. Cell 111: 41–50.
Fujii R, Mutoh M, Niwa K, Yamada K, Aikou T, Nakagawa M et al. (1994). Active efflux system for cisplatin in cisplatin-resistant human KB cells. Jpn J Cancer Res 85: 426–433.
Gekakis N, Staknis D, Nguyen HB, Davis FC, Wilsbacher LD, King DP et al. (1998). Role of the Clock protein in the mammalian circadian mechanism. Science 280: 1564–1569.
Gorbacheva VY, Kondratov RV, Zhang R, Cherukuri S, Gudkov AV, Takahashi JS et al. (2005). Circadian sensitivity to the chemotherapeutic agent cyclophosphamide depends on the functional status of the Clock/BMAL1 transactivation complex. Proc Natl Acad Sci USA 102: 3407–3412.
Gottesman MM, Fojo T, Bates SE . (2002). Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2: 48–58.
Harding HP, Zhang Y, Zeng H, Novoa I, Lu PD, Calfon M et al. (2003). An integrated stress response regulates amino acid metabolism and resistance to oxidative stress. Mol Cell 11: 619–633.
Husain A, He G, Venkatraman ES, Spriggs DR . (1998). BRCA1 up-regulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum(II). Cancer Res 58: 1120–1123.
Ishikawa T, Bao JJ, Yamane Y, Akimaru K, Frindrich K, Wright CD et al. (1996). Coordinated induction of MRP/GS-X pump and gamma-glutamylcysteine synthetase by heavy metals in human leukemia cells. J Biol Chem 271: 14981–14988.
Kohno K, Uchiumi T, Niina I, Wakasugi T, Igarashi T, Momii Y et al. (2005). Transcription factors and drug resistance. Eur J Cancer 41: 2577–2586.
Komatsu M, Sumizawa T, Mutoh M, Chen ZS, Terada K, Furukawa T et al. (2000). Copper-transporting P-type adenosine triphosphatase (ATP7B) is associated with cisplatin resistance. Cancer Res 60: 1312–1316.
Krishnamurthy P, Schuetz JD . (2006). Role of abcg2/bcrp in biology and medicine. Annu Rev Pharmacol Toxicol 46: 381–410.
Kuo MT, Bao J, Furuichi M, Yamane Y, Gomi A, Savaraj N et al. (1998). Frequent coexpression of MRP/GS-X pump and gamma-glutamylcysteine synthetase mRNA in drug-resistant cells, untreated tumor cells, and normal mouse tissues. Biochem Pharmacol 55: 605–615.
Kusaba H, Nakayama M, Harada T, Nomoto M, Kohno K, Kuwano M et al. (1999). Association of 5′ CpG demethylation and altered chromatin structure in the promoter region with transcriptional activation of the multidrug resistance 1 gene in human cancer cells. Eur J Biochem 262: 924–932.
Lai GM, Ozols RF, Young RC, Hamilton TC . (1989). Effect of glutathione on DNA repair in cisplatin-resistant human ovarian cancer cell lines. J Natl Cancer Inst 81: 535–539.
Lee C, Etchegaray JP, Cagampang FR, Loudon AS, Reppert SM . (2001). Posttranslational mechanisms regulate the mammalian circadian clock. Cell 107: 855–867.
Liebermann DA, Hoffman B . (2002). Myeloid differentiation (MyD)/growth arrest DNA damage (GADD) genes in tumor suppression, immunity and inflammation. Leukemia 16: 527–541.
Masuoka HC, Townes TM . (2002). Targeted disruption of the activating transcription factor 4 gene results in severe fetal anemia in mice. Blood 99: 736–745.
Moore RY . (1997). Circadian rhythms: basic neurobiology and clinical applications. Annu Rev Med 48: 253–266.
Murakami T, Shibuya I, Ise T, Chen ZS, Akiyama S, Nakagawa M et al. (2001). Elevated expression of vacuolar proton pump genes and cellular PH in cisplatin resistance. Int J Cancer 93: 869–874.
Nakayama K, Kanzaki A, Ogawa K, Miyazaki K, Neamati N, Takebayashi Y . (2002). Copper-transporting P-type adenosine triphosphatase (ATP7B) as a cisplatin based chemoresistance marker in ovarian carcinoma: comparative analysis with expression of MDR1, MRP1, MRP2, LRP and BCRP. Int J Cancer 101: 488–495.
Ohga T, Koike K, Ono M, Makino Y, Itagaki Y, Tanimoto M et al. (1996). Role of the human Y box-binding protein YB-1 in cellular sensitivity to the DNA-damaging agents cisplatin, mitomycin C, and ultraviolet light. Cancer Res 56: 4224–4228.
Renes J, de Vries EG, Jansen PL, Muller M . (2000). The (patho)physiological functions of the MRP family. Drug Resist Updat 3: 289–302.
Rutkowski DT, Kaufman RJ . (2003). All roads lead to ATF4. Dev Cell 4: 442–444.
Rutter J, Reick M, Wu LC, McKnight SL . (2001). Regulation of clock and NPAS2 DNA binding by the redox state of NAD cofactors. Science 293: 510–514.
Saburi Y, Nakagawa M, Ono M, Sakai M, Muramatsu M, Kohno K et al. (1989). Increased expression of glutathione S-transferase gene in cis-diamminedichloroplatinum(II)-resistant variants of a Chinese hamster ovary cell line. Cancer Res 49: 7020–7025.
Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM . (2006). Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5: 219–234.
Takano H, Kohno K, Matsuo K, Matsuda T, Kuwano M . (1992). DNA topoisomerase-targeting antitumor agents and drug resistance. Anticancer Drugs 3: 323–330.
Tanabe M, Izumi H, Ise T, Higuchi S, Yamori T, Yasumoto K et al. (2003). Activating transcription factor 4 increases the cisplatin resistance of human cancer cell lines. Cancer Res 63: 8592–8595.
Tew KD . (1994). Glutathione-associated enzymes in anticancer drug resistance. Cancer Res 54: 4313–4320.
Tipnis SR, Blake DG, Shepherd AG, McLellan LI . (1999). Overexpression of the regulatory subunit of gamma-glutamylcysteine synthetase in HeLa cells increases gamma-glutamylcysteine synthetase activity and confers drug resistance. Biochem J 337: 559–566.
Torigoe T, Izumi H, Ishiguchi H, Yoshida Y, Tanabe M, Yoshida T et al. (2005). Cisplatin resistance and transcription factors. Curr Med Chem Anticancer Agents 5: 15–27.
Uramoto H, Izumi H, Ise T, Tada M, Uchiumi T, Kuwano M et al. (2002). p73 Interacts with c-Myc to regulate Y-box-binding protein-1 expression. J Biol Chem 277: 31694–31702.
Wang D, Lippard SJ . (2005). Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 4: 307–320.
Yang X, Matsuda K, Bialek P, Jacquot S, Masuoka HC, Schinke T et al. (2004). ATF4 is a substrate of RSK2 and an essential regulator of osteoblast biology; implication for Coffin–Lowry Syndrome. Cell 117: 387–398.
Yao KS, Godwin AK, Johnson SW, Ozols RF, O’Dwyer PJ, Hamilton TC . (1995). Evidence for altered regulation of gamma-glutamylcysteine synthetase gene expression among cisplatin-sensitive and cisplatin-resistant human ovarian cancer cell lines. Cancer Res 55: 4367–4374.
Yoshida A, Takemura H, Inoue H, Miyashita T, Ueda T . (2006). Inhibition of glutathione synthesis overcomes Bcl-2-mediated topoisomerase inhibitor resistance and induces nonapoptotic cell death via mitochondrial-independent pathway. Cancer Res 66: 5772–5780.
Acknowledgements
We thank Dr Rich Simon and Amy Peng for providing the BRB ArrayTools software. The free software was very useful and developed for user-friendly applications. This work was supported in part by the Ministry of Education, Culture, Sports, Science, and Technology of Japan (Mext), Kakenhi (13218132 and 18590307) and a Grant-in-Aid for Cancer Research from the Fukuoka Cancer Society, Japan.
Author information
Authors and Affiliations
Corresponding author
Additional information
Supplementary Information accompanies the paper on the Oncogene website (http://www.nature.com/onc).
Supplementary information
Rights and permissions
About this article
Cite this article
Igarashi, T., Izumi, H., Uchiumi, T. et al. Clock and ATF4 transcription system regulates drug resistance in human cancer cell lines. Oncogene 26, 4749–4760 (2007). https://doi.org/10.1038/sj.onc.1210289
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1210289
Keywords
This article is cited by
-
A novel endoplasmic stress mediator, Kelch domain containing 7B (KLHDC7B), increased Harakiri (HRK) in the SubAB-induced apoptosis signaling pathway
Cell Death Discovery (2021)
-
Subtilase cytotoxin induces a novel form of Lipocalin 2, which promotes Shiga-toxigenic Escherichia coli survival
Scientific Reports (2020)
-
YAP1 enhances NF-κB-dependent and independent effects on clock-mediated unfolded protein responses and autophagy in sarcoma
Cell Death & Disease (2018)
-
ATF4 promotes angiogenesis and neuronal cell death and confers ferroptosis in a xCT-dependent manner
Oncogene (2017)
-
Emodin enhances cisplatin-induced cytotoxicity in human bladder cancer cells through ROS elevation and MRP1 downregulation
BMC Cancer (2016)